Financials in USD. Standardized financial statements.
A compact view of how Cellebrite DI Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $475.68M | $401.20M | $325.11M | $270.65M | $246.25M | $194.91M | $171.85M |
| Revenue Growth? | +18.6% | +23.4% | +20.1% | +9.9% | +26.3% | +13.4% | 0.0% |
| Cost of Revenue? | $75.17M | $62.59M | $53.23M | $50.75M | $42.56M | $37.88M | $35.82M |
| Gross Profit? | $400.50M | $338.61M | $271.88M | $219.91M | $203.69M | $157.03M | $136.03M |
| Gross Margin? | +84.2% | +84.4% | +83.6% | +81.3% | +82.7% | +80.6% | +79.2% |
| Operating Expenses? | $334.02M | $281.70M | $238.64M | $218.86M | $189.87M | $147.82M | $137.55M |
| Operating Income? | $66.48M | $56.91M | $33.24M | $1.04M | $13.82M | $9.22M | -$1.52M |
| EBITDA? | $103.07M | -$265.35M | -$65.41M | $130.10M | $89.47M | $17.28M | $5.62M |
| Income Before Tax | $90.68M | -$275.98M | -$75.56M | $120.76M | $82.31M | $11.40M | $1.42M |
| Income Tax Expense | $12.35M | $7.02M | $5.54M | -$45,000 | $10.91M | $5.62M | $3.29M |
| Net Income? | $78.33M | -$283.01M | -$81.10M | $120.81M | $71.40M | $5.78M | -$1.88M |
| EPS? | $0.32 | $-1.35 | $-0.43 | $0.64 | $0.50 | $-0.05 | $-0.05 |
| Diluted EPS? | $0.31 | $-1.35 | $-0.43 | $0.59 | $0.44 | $-0.05 | $-0.05 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality